SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
Domestic Metals Completes Surface IP Geophysical Survey at Smart Creek and Announces Amendment to Warrant Terms of Unit Private Placement
RETRANSMISSION: West High Yield Resources Ltd. Signs Definitive Forward Sales Agreement to Sell Magnesium Ore from Its Record Ridge Project
Anteros Metals Reports Assay Results from RM26-01 and Provides Exploration Update at the Seagull Critical Minerals Project, Ontario
